EyePoint Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
EyePoint Pharmaceuticals, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2010 to Q3 2025.
  • EyePoint Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2025 was -$59.7M, a 103% decline year-over-year.
  • EyePoint Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was -$131M, a 84.9% decline from 2023.
  • EyePoint Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$70.7M, a 30.8% increase from 2022.
  • EyePoint Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$102M, a 75% decline from 2021.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)

EyePoint Pharmaceuticals, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$59.7M -$30.4M -103% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 -$59.3M -$28.5M -92.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q3 2024 -$29.4M Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 -$30.8M Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q2 2017 -$18.5M -$6.12M +$309K +4.81% Apr 1, 2017 Jun 30, 2017 10-K 2020-03-16
Q1 2017 -$18.8M -$5.14M -$65K -1.28% Jan 1, 2017 Mar 31, 2017 10-Q 2017-05-08
Q4 2016 -$18.7M -$67K +$5.16M +98.7% Oct 1, 2016 Dec 31, 2016 10-Q 2017-02-09
Q3 2016 -$23.9M -$7.16M -$2.19M -44% Jul 1, 2016 Sep 30, 2016 10-Q 2016-11-08
Q2 2016 -$21.7M -$6.43M -$1.23M -23.7% Apr 1, 2016 Jun 30, 2016 10-KT 2019-03-18
Q1 2016 -$20.5M -$5.08M -$33K -0.66% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-08
Q4 2015 -$20.4M -$5.23M -$1.12M -27.1% Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
Q3 2015 -$19.3M -$4.97M -$25.8M -124% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-08
Q2 2015 $6.44M -$5.19M -$1.18M -29.5% Apr 1, 2015 Jun 30, 2015 10-K 2017-09-13
Q1 2015 $7.63M -$5.04M -$2.82M -127% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-06
Q4 2014 $10.5M -$4.11M -$573K -16.2% Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-09
Q3 2014 $11M $20.8M +$24.5M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 -$13.5M -$4.01M -$31K -0.78% Apr 1, 2014 Jun 30, 2014 10-K 2016-09-13
Q1 2014 -$13.5M -$2.22M +$591K +21% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08
Q4 2013 -$14M -$3.54M -$895K -33.8% Oct 1, 2013 Dec 31, 2013 10-Q 2015-02-06
Q3 2013 -$13.2M -$3.72M -$1.13M -43.8% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-07
Q2 2013 -$12M -$3.98M -$1.68M -72.9% Apr 1, 2013 Jun 30, 2013 10-K 2015-09-10
Q1 2013 -$10.3M -$2.81M -$93K -3.42% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-14
Q4 2012 -$10.2M -$2.65M +$14.9M +84.9% Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-12
Q3 2012 -$25.1M -$2.58M -$102K -4.11% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-13
Q2 2012 -$25M -$2.3M -$2.01M -697% Apr 1, 2012 Jun 30, 2012 10-K 2014-09-11
Q1 2012 -$23M -$2.72M +$82K +2.93% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-14
Q4 2011 -$23.1M -$17.5M -$14.8M -558% Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-08
Q3 2011 -$8.23M -$2.48M +$617K +19.9% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-09
Q2 2011 -$8.85M -$289K Apr 1, 2011 Jun 30, 2011 10-K 2013-09-27
Q1 2011 -$2.8M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-10
Q4 2010 -$2.66M Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-09
Q3 2010 -$3.1M Jul 1, 2010 Sep 30, 2010 10-Q/A 2011-11-09

EyePoint Pharmaceuticals, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$131M -$60.1M -84.9% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-06
2023 -$70.7M +$31.5M +30.8% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-06
2022 -$102M -$43.8M -75% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-08
2021 -$58.4M -$13M -28.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-10
2020 -$45.4M +$11.4M +20.1% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-14
2019 -$56.8M -$3.62M -6.81% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-12
2018 -$53.2M -$34.7M -188% Jul 1, 2017 Jun 30, 2018 10-K 2020-03-16
2017 -$18.5M +$3.22M +14.8% Jul 1, 2016 Jun 30, 2017 10-K 2020-03-16
2016 -$21.7M -$28.1M -437% Jul 1, 2015 Jun 30, 2016 10-KT 2019-03-18
2015 $6.44M +$19.9M Jul 1, 2014 Jun 30, 2015 10-K 2017-09-13
2014 -$13.5M -$1.47M -12.2% Jul 1, 2013 Jun 30, 2014 10-K 2016-09-13
2013 -$12M +$13M +51.9% Jul 1, 2012 Jun 30, 2013 10-K 2015-09-10
2012 -$25M -$16.2M -183% Jul 1, 2011 Jun 30, 2012 10-K 2014-09-11
2011 -$8.85M -$17.6M -201% Jul 1, 2010 Jun 30, 2011 10-K 2013-09-27
2010 $8.78M Jul 1, 2009 Jun 30, 2010 10-K 2012-09-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.